Taltz^®

(Ixekizumab) Eli Lilly

Composition:

•   Available as solution for injection in pre-filled pen containing 80 mg of ixekizumab per 1 mL of solution

Indication(s):

• Newly indicated for the treatment of adult patients with active ankylosing spondylitis (radiographic axial spondyloarthritis) who have responded inadequately to conventional therapy

•   Newly indicated for the treatment of adult patients with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C reactive protein (CRP) and/or magnetic resonance imaging (MRI) who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs)

•   Also indicated:

o For the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy

o Alone or in combination with methotrexate for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti- rheumatic drug (DMARD) therapies